Need help with B2B Marketing?
Let the smarketers’ team drive your pipeline with data-led campaigns and AI-powered growth strategies.
In brief: HubSpot for pharma and life sciences is viable for mid-sized commercial teams in biotech, medtech, diagnostics, and health tech – but only inside a deliberately tiered architecture. HubSpot manages the commercial tier: marketing, HCP engagement, business development, and partner relationships. Validated systems handle clinical, quality, and pharmacovigilance records. Patient health information never enters the marketing CRM. Compliance is enforced through architecture and field design, not policy alone.
A life sciences marketing ops lead gets the same request from three directions in one week. Sales wants every HCP conversation logged in one place. Legal wants proof that no patient-adjacent data ever touches the marketing stack. The CFO wants to know why the company pays for four systems that do not talk to each other. The CRM decision sits in the middle of all three, and getting it wrong is not a productivity problem in this industry. It is an audit finding.
This article is for teams asking a specific question: can HubSpot for pharma and life sciences commercial operations carry the full weight of a regulated business without creating compliance exposure? The short version is yes, for a defined set of jobs, inside a deliberately tiered architecture. The longer version, including where HubSpot should never be the system of record, is what follows. It draws on our HubSpot implementation work as a PLATINUM Solutions Partner, including engagements across our life sciences and health tech client base whose results appear later in this piece.
What Does Pharma CRM Compliance Actually Require?
Pharma CRM compliance requires navigating four regulatory frames simultaneously, and each one constrains a different part of the system. In brief: HubSpot for pharma and life sciences must address health data protection (HIPAA), consent and privacy law (GDPR), electronic records integrity (21 CFR Part 11/GxP), and transparency reporting for HCP transfers of value.
- Health data protection (HIPAA and equivalents). If any workflow can touch protected health information, patient identifiers, condition data, anything patient-adjacent, that data needs contractual and technical safeguards the standard marketing stack was not designed for. The cleanest answer for most commercial teams is architectural: keep PHI out of the marketing CRM entirely, and enforce that with field design and intake rules rather than policy documents alone.
- Consent and privacy law (GDPR and successors). HCPs, patients, payers, and channel partners each need a distinct consent model with a documented lawful basis. A single opt-in checkbox does not survive scrutiny when your database mixes prescribers with procurement contacts.
- Electronic records integrity (21 CFR Part 11 and GxP). Systems that hold regulated records, trial data, quality records, submissions, must be validated, access-controlled, and audit-trailed to a standard commercial CRMs do not certify against. This is the boundary line: validated systems on one side, commercial systems on the other, with controlled traffic between them.
- Transparency reporting. Payments and transfers of value to HCPs are reportable in major markets. Your CRM does not have to file the report, but it must never contradict it. Interaction records need dates, contexts, and values that reconcile with what compliance reports externally.
Notice what is not on the list: any requirement that the marketing CRM itself be a validated GxP system. That distinction is what makes HubSpot viable in this industry. The commercial tier and the regulated tier are different systems with different rules, and the architecture exists to keep them that way.
Key takeaway: For any CRM for regulated industries, compliance does not ask which platform you use. It asks whether regulated data can leak into it, and whether you can prove it did not. Both are architecture questions, settled before the first contact record is created.
Where HubSpot for Pharma and Life Sciences Fits in Your Stack (and Where It Does Not)
Is HubSpot suitable for pharma and life sciences? For the commercial tier, marketing, business development, partner and HCP engagement that does not involve PHI, it is a strong fit, and often the pragmatic one. For the validated tier, clinical, quality, pharmacovigilance, it is not a candidate and should not be forced into becoming one.
The market context explains why the question comes up so often. HubSpot ended 2025 with roughly 288,700 customers and $3.13B in revenue, growing 19% year over year, and holds about 38% of the marketing automation market. Salesforce still leads overall CRM share at roughly 20.7% by IDC’s measure, and its life sciences ecosystem (including the Veeva lineage) remains the default for large pharma field forces. Meanwhile CRM adoption keeps growing at about 12.6% per year, which means more mid-sized life sciences companies are making this decision for the first time. For multi-region teams already operating on HubSpot, the architecture challenges multiply further – we cover those decisions in our multi-region HubSpot implementation guide.
The honest way to frame the HubSpot life sciences CRM decision is by company profile and job to be done, not by feature checklists:
| Scenario | Better default | Why |
|---|---|---|
| Large pharma with a field force running samples, call plans, and rep-triggered emails at scale | Life-sciences-specific CRM (Veeva-class) | Purpose-built HCP data models, validated processes, and industry integrations already exist |
| Mid-sized biotech, medical device, diagnostics, or health tech commercial team | HubSpot commercial tier + separate validated systems | Faster deployment, lower admin burden, strong automation, compliance handled by architecture |
| Health tech / SaaS selling into providers and payers | HubSpot as primary CRM | The buying motion is B2B, not HCP promotion; regulated data rarely needs to enter the CRM at all |
| Clinical operations, quality, pharmacovigilance records | Validated GxP systems only | These records require validation and audit standards no commercial CRM certifies against |
One more market force pushes regulated companies toward better CRM discipline: buyers increasingly self-serve. Gartner found 67% of B2B buyers prefer a rep-free buying experience, and Forrester reports 94% of B2B buyers use generative AI during the purchase process. In life sciences, self-directed research happens under the same promotional rules as everything else, which means the content, forms, and nurture paths your CRM orchestrates are themselves regulated surfaces. The system managing them needs guardrails, not just features.
How to Track HCP Interactions in HubSpot Without Compliance Exposure
The core discipline is simple to state: record the interaction, not the patient. Effective HCP engagement in HubSpot starts with the record design: who the professional is, what was discussed at the category level, what materials were shared, what consent exists, and what value, if any, changed hands. It never captures patient cases, prescribing behavior tied to individuals, or clinical details that drift toward PHI.
In practice, that means configuring the portal before importing a single contact:
- Custom objects for engagements. Model HCP interactions, advisory sessions, congress meetings, and speaker events as structured objects with controlled fields, so free-text notes are the exception rather than the default. Free text is where compliance problems hide.
- Field-level permissions and property validation. Restrict who can create or edit sensitive properties, and use validation rules to block obvious PHI patterns from entering notes fields.
- Consent as data, not memory. Store consent type, date, channel, and scope on the record. Communication eligibility should be computed from those fields, so an expired or withdrawn consent switches off every dependent workflow automatically.
- Transfer-of-value fields. If your team hosts HCP events or advisory boards, capture the reportable details in structured fields that reconcile with the compliance team’s transparency reporting, in whatever system files it.
Teams that do this well get something the spreadsheet era never gave them: a single engagement history per stakeholder that legal can audit in minutes. Teams that skip it get a CRM that is technically clean and practically unusable in an inspection.
How to Run HubSpot Marketing Automation in Regulated Pharma Environments
Automation is where regulated marketers get nervous, and where most of HubSpot’s value actually sits. The resolution is to automate delivery, never approval. Content review (MLR or its local equivalent) stays a human process with documented sign-off; automation handles what happens after approval, at scale and with an audit trail.
The working rules we implement for life sciences clients:
- Approved-asset library only. Workflows and sequences may reference only content that carries an approval ID and expiry date. When approval lapses, the asset is retired from every workflow that uses it, in one place.
- Segmentation by consent and audience class. HCP nurtures, partner communications, and general corporate content run on separate lists with separate consent logic. No shared “master list,” ever.
- Conservative personalization. Personalize by role, institution type, and declared interest. Do not personalize by inferred clinical behavior; the compliance cost outweighs the click-through gain.
- Quarterly workflow audits. Every live workflow gets an owner, a purpose statement, and a review date. Orphaned automation is the regulated marketer’s silent risk.
Smarketers insight: The pattern we see across HubSpot implementations for life sciences clients: companies over-restrict content creation and under-restrict automation plumbing. Reversing that, generous with approved content, strict with workflow governance, raises output and lowers risk at the same time.
How Should HubSpot Integrate With Clinical Trial and Quality Systems?
The integration question has one governing principle: the validated tier and the commercial tier connect through narrow, documented, one-directional interfaces, or not at all. HubSpot should never write into a validated system, and validated systems should send the commercial tier only what commercial teams legitimately need.
Three integration patterns cover most real cases:
- Site and investigator relations. Trial site outreach and investigator communications can run in HubSpot as ordinary professional relationship management, with study-level data staying in the CTMS. What crosses the boundary is contact and engagement data, not trial data.
- Recruitment marketing hand-off. Where marketing supports trial recruitment, HubSpot can manage awareness campaigns up to the point of pre-screening. The moment a respondent provides health information, they exit the marketing stack into a system built to hold it. The form architecture must enforce that hand-off, not rely on it happening later.
- Commercial launch coordination. Around launch, medical affairs, market access, and marketing all need visibility into overlapping stakeholders – a challenge we address separately in our guide to ABM for CDMOs and CROs in pharma. A middleware layer (iPaaS) with documented field mappings keeps each system authoritative for its own domain, with a named data owner for the sync itself.
If a vendor tells you these boundaries are unnecessary friction, that is a sales pitch, not an architecture. The friction is the compliance.
The Regulated Revenue Stack: A 6-Step HubSpot Implementation for Life Sciences
When implementing HubSpot for pharma and life sciences clients, we follow a fixed sequence called the Regulated Revenue Stack. The order matters because every later step inherits the decisions of the earlier ones, and retrofitting data classification into a live portal is the most expensive way to do it.
Step 1. Classify your data. Before any tooling decision, inventory what data the commercial team touches and mark what is PHI, what is regulated record, and what is ordinary business contact data. Only the third category enters HubSpot.
Step 2. Map consent by audience. Define the consent model per audience class (HCP, partner, payer, general professional) with legal, and encode it as CRM properties from day one.
Step 3. Tier your systems. Declare in writing which system is authoritative for what. Validated systems keep their validation; HubSpot owns the commercial tier.
Step 4. Configure the guardrails. Permission sets, field-level controls, validation rules, approved-content libraries, and audit-friendly logging, all before go-live.
Step 5. Wire the integrations. Narrow, documented, one-directional syncs with a named owner. Anything bidirectional needs a written justification.
Step 6. Document and train. SOPs for the portal, an MLR-to-workflow procedure, and role-based onboarding. The configuration only protects you if the people using it understand why it exists.
Case Study: Compliance-Aware Inbound That Grew 8X
Eclat Health, a healthcare BPO serving US providers, came to us with the constraint every company in this article recognizes: grow inbound demand without ever letting patient-adjacent data drift into the marketing stack. Their pipeline depended on paid spend with a rising cost per lead, and their site content answered almost none of the questions their buyers actually researched.
We rebuilt the commercial tier along the architecture above: clean data classification at every intake point, consent captured as structured fields, and HubSpot workflows running only approved content mapped to the questions provider-side buyers ask. Paid spend was reallocated toward the segments the CRM showed were converting.
Result: Eclat Health saw 8X growth in inbound results, cost per lead cut from $5.00 to $1.82 (a 63.6% reduction), and site traffic up 200%, all within a stack their compliance team could audit end to end without exceptions. (See the full Eclat Health case study on our success stories page.)
The same pattern held for KeyReply, a healthcare AI platform selling into hospital systems. Read the KeyReply ABM campaign case study for the full breakdown: 100+ MQLs in six months with cost per lead cut from $75 to $51.86, driven by the same combination of structured CRM foundations and content built for how healthcare buyers research.
When Is HubSpot for Pharma Not the Right CRM Choice?
A decision-stage article owes you the disqualifiers, so here they are.
- If your commercial model is a large field force running detailed HCP call plans, sample management, and rep-triggered promotional email at national scale, a life-sciences-specific CRM is the safer default. Rebuilding that machinery in HubSpot means custom-building what a vertical vendor ships as standard.
- If your legal team requires validated-system treatment for all customer data, not just regulated records, HubSpot’s commercial-tier positioning does not meet that bar, and no amount of configuration changes it.
- If nobody owns the architecture, do not start. A tiered model only works with a named owner for data classification and integrations. Without one, HubSpot’s ease of use becomes the risk: it makes it easy for well-meaning teams to create fields and forms that quietly cross the line.
And a caveat on this article itself: regulatory specifics vary by market and by product class, and platform capabilities change. Treat the architecture here as the durable part, and verify current platform terms, data processing agreements, and your own counsel’s reading before you commit.
Where to Start
The useful first step costs a week, not a quarter: run the data classification exercise from Step 1 against your current stack, and list every place regulated or patient-adjacent data could enter a marketing system today. Most teams find at least one form, sync, or spreadsheet that fails the test, and fixing it improves your position whatever CRM you choose.
If you want that review done by a team that has built this HubSpot architecture before, book a Free Pharma CRM Review. We will map your data tiers, flag the exposure points, and give you a build order you can execute with or without us.
Frequently Asked Questions
How long does a compliant HubSpot implementation take for a life sciences company?
A compliant HubSpot for pharma and life sciences implementation takes 8-14 weeks for a mid-sized commercial team. That breaks down as: two to three weeks of data classification and consent design, four to six weeks of configuration and integration, and the remainder for documentation, training, and controlled migration. Compressing the first phase is the most common and most expensive mistake.
What does this typically cost beyond HubSpot licensing?
Implementation for a regulated setup usually runs 1.5X to 3X what an unregulated B2B build costs, because classification, guardrail configuration, and documentation are real workstreams. Budget separately for middleware if you are integrating with clinical or quality systems.
Do we need legal or compliance involved from the start?
Yes, at two specific points: approving the data classification and consent model before configuration, and reviewing the SOPs before go-live. Involving them only at the end converts a two-day review into a rebuild.
Can HubSpot store any health-related information at all?
HubSpot can store professional contact data and commercial engagement history. Patient-level health information should stay out of the marketing CRM entirely, enforced by form design and field validation – not policy alone. Whether HubSpot qualifies as a HIPAA-compliant CRM for pharma data on your specific tier is a question for current platform terms and your legal counsel – verify rather than assume.
How do we handle HCP consent across multiple countries?
Model consent as structured properties (type, scope, date, channel, jurisdiction) and compute communication eligibility from them per market. One global opt-in flag cannot represent the differences between, for example, EU and US consent standards, and it will fail the first audit that looks closely.
What should stay in our validated systems rather than HubSpot?
Anything that is a regulated record: trial data, quality records, pharmacovigilance cases, submissions, and signed investigator documentation. HubSpot holds professional contact data and engagement history for the commercial relationship, nothing that requires 21 CFR Part 11 treatment.
Which KPIs prove the CRM investment to leadership?
Cost per lead and cost per opportunity by segment, MQL-to-SQL conversion, speed of audit response (time to produce a complete engagement history), and pipeline sourced from inbound. The Eclat Health engagement above moved exactly these numbers: CPL down 63.6% and inbound up 8X.
Can we migrate from a life sciences CRM like Veeva to HubSpot?
Sometimes, but check the motion first. If you are moving away from a field-force promotional model toward digital-first commercial engagement, migration can simplify your stack. If the field-force model remains core, keep the vertical CRM and let HubSpot run the marketing tier beside it.
Venugopal Mamidala
Director of MarTech
